Immatics imagines broader CAR-T pipeline with another Bristol Myers pact and addition to 2019 TCR deal

Kyle LaHucik

Senior Reporter

Immatics is hitting the gas pedal on another Bristol Myers Squibb deal as the biotech-Big Pharma pair also level up their 2019 pact, originally inked …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Immatics imagines broader CAR-T pipeline with another Bristol Myers pact and addition to 2019 TCR deal

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Im­mat­ics imag­ines broad­er CAR-T pipeline with an­oth­er Bris­tol My­ers pact and ad­di­tion to 2019 TCR deal

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Immatics imagines broader CAR-T pipeline with another Bristol Myers pact and addition to 2019 TCR deal

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival